Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01227694
Other study ID # XCEL-M-09-01
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received October 22, 2010
Last updated December 10, 2015
Start date October 2010
Est. completion date January 2013

Study information

Verified date November 2015
Source Banc de Sang i Teixits
Contact n/a
Is FDA regulated No
Health authority Spain: Spanish Agency of Medicines
Study type Interventional

Clinical Trial Summary

This is a prospective, open-label, single-dose, single-arm phase I-II study in which 15 patients diagnosed with gonarthrosis grade II-III (Kellgren and Lawrence) will enter the study with the primary objective of assessing the feasibility and safety of the knee articular infiltration of autologous bone marrow mesenchymal stem cells (MSC). Secondary objectives are to assess the efficacy by imaging procedures and clinical questionnaires.

MSC obtained from each patient's bone marrow will be isolated and expanded "Ex-Vivo" under GMP conditions at Xcelia-División de Terapias avanzadas del Banc de Sang I Teixits. After 21 days, patients will be implanted a single-dose of approximately 40 millions of autologous MSC in the knee by articular injection, and followed up for 12 month. Articular cartilage changes will be determined by T2-weighted MRI (Cartigram) at 6 and 12 month. Clinical assessment will measure the pain by the visual analogue scale (VAS), the self-reported functional status by Heath Assessment Questionnaire (HAQ), and the quality of life by Short Form 36 questionnaire (SF-36) at 3, 6 and 12 month.

The working hypothesis proposes that the expected regenerative articular cartilage effect of the MSC will be produced to a measurable degree by imaging procedures and clinical questionnaires.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date January 2013
Est. primary completion date July 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Gonarthrosis grade II-III of Kellgren and Lawrence assessed by two observers

2. Chronic knee pain with mechanical characteristics

3. Absence of local or systemic septic process

4. Haematological and biochemical laboratory tests without significant alterations that contraindicate treatment.

5. Informed Consent form signed by the patient

6. The patient is able to understand the nature of the study

Exclusion Criteria:

1. Patients < 18 years or legally dependent

2. Patients >65 years

3. Previous surgery of the knee

4. Intraarticular treatment in the past 6 month

5. Knee ligament or meniscus rupture observed by MRI

6. Any sign of infection

7. Positive serology for HIV-1 or HIV-2, Hepatitis B (HBsAg), Hepatitis C (Anti-HCV-Ab) and syphilis.

8. Congenital or acquired malformation resulting in significant deformity of the knee and leading to problems in application or evaluation of results.

9. Overweight expressed as body mass index (BMI) greater than 30.5 (obesity grade II). BMI estimated as mass (kg) / corporal surface (m2).

10. Pregnant women or intend to become pregnant or breast-feeding

11. Neoplasia

12. Immunosuppressive states

13. Participation in another clinical trial or treatment with a different investigational product within 30 days prior to inclusion in the study.

14. Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Other:
Autologous MSC knee implantation
Isolation and "Ex-Vivo" expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection.

Locations

Country Name City State
Spain Centro Medico Teknon-ITRT Barcelona

Sponsors (4)

Lead Sponsor Collaborator
Banc de Sang i Teixits Centro Medico Teknon, Cetir Sant Jordi, S.a.., Institut de Terapia Regenerativa Tissular

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of autologous bone marrow mesenchymal stem cells (MSC) knee articular infiltration. Feasibility will be assessed by checking the cascade of procedures (from bone marrow extraction to MSC implantation) and confirming the global process is viable. 12 months Yes
Primary Safety of autologous bone marrow mesenchymal stem cells (MSC) knee articular infiltration. Safety will be assessed by collecting adverse events throughout the experimental phase, including the follow-up at 12 months. 12 months Yes
Secondary Efficacy by imaging procedures. Articular cartilage changes will be determined by T2-weighted MRI (Cartigram). 6 months No
Secondary Efficacy by imaging procedures. Articular cartilage changes will be determined by T2-weighted MRI (Cartigram). 12 month No
Secondary Clinical outcomes. Clinical assessment will measure the pain by the visual analogue scale (VAS), the self-reported functional status by Heath Assessment Questionnaire (HAQ), and the quality of life by Short Form 36 questionnaire (SF-36). 3 month Yes
Secondary Clinical outcomes. Clinical assessment will measure the pain by the visual analogue scale (VAS), the self-reported functional status by Heath Assessment Questionnaire (HAQ), and the quality of life by Short Form 36 questionnaire (SF-36). 6 months Yes
Secondary Clinical outcomes. Clinical assessment will measure the pain by the visual analogue scale (VAS), the self-reported functional status by Heath Assessment Questionnaire (HAQ), and the quality of life by Short Form 36 questionnaire (SF-36). 12 months Yes
See also
  Status Clinical Trial Phase
Recruiting NCT03895489 - Effectiveness of the Journey Total Knee Arthroplasty Versus Two Standard of Care Total Knee Arthroplasty Prostheses N/A
Completed NCT03660943 - A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain Phase 3
Completed NCT04531969 - Comparison of Outpatient and Inpatient Spa Therapy N/A
Completed NCT02848027 - Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment Phase 3
Completed NCT05160246 - The Instant Effect of Kinesiology Taping in Patients With Knee OA N/A
Recruiting NCT06080763 - Biomechanics and Clinical Outcomes in Responders and Non-Responders
Completed NCT03643588 - The Comparison of HYAJOINT Plus and Hyalgan Hyaluronan Supplement for Knee Osteoarthritis Pain N/A
Active, not recruiting NCT05100225 - Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis Phase 2
Active, not recruiting NCT04061733 - New Hydroxyethyl Cellulose Hydrogel for the Treatment of the Pain of Knee Arthrosis N/A
Completed NCT04051489 - A Novel Smartphone Application for "Smart" Knee Osteoarthritis Trials
Recruiting NCT05546541 - Epidemiology and Nutrition
Recruiting NCT05447767 - Prediction AlgoriThm for regeneraTive Medicine Approach in knEe OA: New Decision-making Process Based on Patient pRofiliNg Phase 2
Not yet recruiting NCT04448106 - Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis Phase 2
Not yet recruiting NCT03225911 - Effect of a Lateral Wedge Insole and Simple Knee Sleeve in Individuals With Knee Osteoarthritis N/A
Completed NCT05070871 - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women N/A
Completed NCT05703087 - Positive Cueing in Knee Arthroplasty. N/A
Not yet recruiting NCT06042426 - Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population Phase 4
Terminated NCT02909257 - Motor-Sparing Femoral Nerve Block Dose Phase 4
Completed NCT02901964 - Effect of Strengthening the Hip Abductor in Patients With Knee Osteoarthritis: Randomized Controlled Trial N/A
Completed NCT02944448 - A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee Phase 2